by Barry101 | Oct 26, 2022 | Press Release
Corrects the Record Regarding Activist Group’s False and Misleading Statements Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the “Face of the Activist” to Help Them “Get Control” Without Paying a Premium to All...
by Barry101 | Oct 12, 2022 | Press Release, Uncategorized
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of...
by Barry101 | Sep 21, 2022 | Press Release, Uncategorized
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ETOCALA,...
by Barry101 | Sep 19, 2022 | Press Release, Uncategorized
Highlights Significant Progress Made in Recent Years – and Especially Over Past 18 Months – in Repurposing Lead Drug Ampligen in Oncology to Benefit Patients and All Shareholders Calls on Shareholders to Support Continued Positive Momentum by Re-Electing...
by Barry101 | Sep 7, 2022 | Press Release, Uncategorized
OCALA, Fla., Sept. 07, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Sep 6, 2022 | Press Release, Uncategorized
OCALA, Fla., Sept. 06, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
